FDA Reviews Imvanex and JYNNEOS Vaccines for Smallpox

Imvanex: A Proven Option

Imvanex vaccine, also known by the brand name Imvamune, is licensed by the FDA for protecting adults against smallpox.

It contains an attenuated (weakened) form of the vaccinia virus, which triggers the body's immune response.

The FDA has initiated a review of JYNNEOS smallpox vaccine, which is also known as Imvanex in the European Union (EU).

The European Medicines Agency's (EMA) human medicines committee (CHMP) is assessing data to expand the approved uses of JYNNEOS.

The FDA and CHMP are working with the Strategic Advisory Group of Experts (SAGE) on interim guidance for the potential use of smallpox vaccines.